Add to a list

Inactive Instrument

Biocorrx Inc Stock Other OTC

US09073C1062

Healthcare Facilities & Services

on all subscriptions*

Last hours

Enjoy this offer

* See conditions under "Our services"

BioCorRx Inc. is an addiction treatment solutions company. The Company is engaged in offering treatment for substance use and other related disorders. Its Beat Addiction Recovery is a substance use disorder recovery program that typically includes its Cognitive Behavioral Therapy (CBT) modules along with peer support via mobile app, along with medication prescribed by an independent treating physician under their discretion. The UnCraveRx Weight Loss Program is also a medication-assisted weight-loss program that includes access to concierge on-demand wellness specialists, nutritionists, fitness experts, and personal support from behavioral experts. It also controls BioCorRx Pharmaceuticals Inc., a clinical-stage drug development subsidiary, which is seeking FDA approval for BICX104, an implantable naltrexone pellet for the treatment of alcohol and opioid use disorders. It is also engaged in the establishment of alcoholism and opioid addiction rehabilitation and treatment centers.

Employees

Sector

Healthcare Facilities & Services

More about the company

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!

SEIZE THE OFFER!

Market Cap	9.59M 8.35M 7.7M 7.24M 13.55M 904M 13.65M 91.63M 35.58M 445M 35.99M 35.22M 1.54B	P/E 2024	-0.78x	P/E 2025	-1.56x
Enterprise Value	11.59M 10.1M 9.31M 8.76M 16.38M 1.09B 16.5M 111M 43.01M 538M 43.5M 42.57M 1.87B	EV / Sales 2024	1,004x	EV / Sales 2025	11.4x
Free-Float	38.64%	Yield 2024 *	-	Yield 2025	-

05-15	BioCorRx Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
03-31	BioCorRx Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-31	BioCorRx Inc. Auditor Raises 'Going Concern' Doubt	CI
01-06	BioCorRx Inc. Announces Board Changes, Effective January 1, 2026	CI
11-15	BioCorRx Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
14/08/25	BioCorRx Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
29/07/25	BioCorRx Inc. announced that it has received $0.35 million in funding	CI
15/05/25	BioCorRx Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
31/03/25	BioCorRx Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
31/03/25	BioCorRx Inc. Auditor Raises 'Going Concern' Doubt	CI
14/11/24	BioCorRx Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	CI
13/08/24	BioCorRx Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	CI
15/05/24	BioCorRx Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

12-10	BioCorRx Inc. to Present at the Life Sciences Virtual Investor Forum December 11th	AQ
15/08/24	BioCorRx Reports Business Update for the Second Quarter of 2024	AQ
16/05/24	BioCorRx Reports Business Update for the First Quarter of 2024	AQ
03/04/24	BioCorRx Pharmaceuticals Inc. Awarded New Patent for Novel Compound to Treat Pain, Depression, and Schizophrenia	AQ
02/04/24	BioCorRx Reports Business Update for 2023	AQ

Manager	Title	Age	Since
Lourdes Felix CEO	Chief Executive Officer	58	09/11/2020
Louis Lucido PSD	President	77	05/01/2024

Director	Title	Age	Since
Lourdes Felix BRD	Director/Board Member	58	07/03/2013
Kent Emry CHM	Chairman	57	-
Louis Lucido BRD	Director/Board Member	77	01/03/2019

Biocorrx Inc Stock Other OTC

Stocks

US09073C1062

Healthcare Facilities & Services

Valuation: Biocorrx Inc

Latest news : Biocorrx Inc

Press Releases: Biocorrx Inc

Quotes and Performance

Managers and Directors: Biocorrx Inc

Other Healthcare Facilities & Services

Financials

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
BIOCORRX INC	-15.84%	+6.09%	-	-	9.59M
CVS HEALTH CORPORATION	-0.85%	-2.15%	+47.10%	+45.19%	125B
HCA HEALTHCARE, INC.	-3.35%	-0.88%	-0.45%	+29.33%	83.23B
FRESENIUS SE & CO. KGAA	+0.52%	+5.07%	-4.92%	+55.28%	25.41B
QUEST DIAGNOSTICS INCORPORATED	-1.40%	-4.33%	+8.47%	+40.69%	21.59B
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY	+0.05%	+2.59%	-9.12%	-22.77%	20.34B
TENET HEALTHCARE CORPORATION	-3.32%	-0.35%	+2.98%	+120.03%	14.86B
REDE D'OR SÃO LUIZ S.A.	+0.24%	-2.32%	-5.73%	+0.06%	14.14B
DAVITA INC.	-1.27%	+2.00%	+53.11%	+112.98%	13.35B
FRESENIUS MEDICAL CARE AG	-1.70%	+2.29%	-11.97%	-5.50%	12.72B
Average	-2.66%	+0.78%	+8.83%	+41.70%	36.79B
Weighted average by Cap.	-1.45%	-0.50%	+18.92%	+39.73%

	2024	2025
Net sales	7.66K 6.68K 6.16K 5.79K 10.83K 722K 10.91K 73.25K 28.45K 356K 28.77K 28.15K 1.23M	797K 695K 640K 602K 1.13M 75.14M 1.13M 7.62M 2.96M 37.03M 2.99M 2.93M 128M
Net income	-5.11M -4.45M -4.1M -3.86M -7.22M -481M -7.27M -48.79M -18.95M -237M -19.17M -18.76M -822M	-3.44M -3M -2.76M -2.6M -4.86M -324M -4.9M -32.87M -12.77M -160M -12.91M -12.64M -554M
Net Debt	2.72M 2.37M 2.18M 2.05M 3.84M 256M 3.87M 25.98M 10.09M 126M 10.2M 9.98M 438M	2M 1.74M 1.61M 1.51M 2.83M 189M 2.85M 19.12M 7.43M 92.95M 7.51M 7.35M 322M